Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092068 | 0.99 | NPC1 (0.51) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL2091046 | 0.85 | KDM4E (0.44) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL2089548 | 0.84 | KDM4E (0.45) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL2089307 | 0.80 | NPC1 (0.50) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL2091087 | 0.79 | NPC1 (0.54) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL2089627 | 0.77 | GRIN2B (0.48) | NPC1POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2091095 | 0.77 | RAB9A (0.43) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2091937 | 0.76 | GRIN2B (0.47) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL2092083 | 0.76 | TGM2 (0.43) | NPC1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL3960950 | 0.75 | CCNE1 (0.47) | NPC1POLBMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | SCANIO MARC J C (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163914-B2 | Modulate neuronal nicotinic receptor activity; attention deficit disorder, Parkinson's, Tourette's, schizophrenia, cognitive deficits, dementia; acute pain, post-surgical pain, chronic pain, inflammatory pain; 2-[1-azatricyclo[3.3.1.13,7]dec-4-ylidene]-N-(4-methylphenyl)acetamide | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2069346-B1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | NAAA, AADAC, CD38 | NPC1 3584/4885POLB 969/4885MEN1 911/4885 |
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | NAAA, AADAC, CD38 | NPC1 3584/4885POLB 969/4885MEN1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.